Intestinal metaplasia is a change in which the normal cells of the stomach lining take on features resembling those of intestinal cells over time. It usually develops on a background of long-standing chronic gastritis.
One of the most important causes is Helicobacter pylori (H. pylori) infection. Atrophic gastritis, autoimmune gastritis and some environmental factors can also play a part in its development.
Is intestinal metaplasia common?
Yes. It is seen more often in populations where H. pylori infection and stomach cancer are more common. Its frequency varies considerably with age, country, H. pylori prevalence, and which patients and which parts of the stomach the biopsies were taken from.
In a large AGA review, intestinal metaplasia was found on routine stomach biopsies in about 4.8% of cases. But this figure cannot be applied directly to every population, particularly countries where H. pylori is more common.
The likelihood of finding it increases with age.
Is intestinal metaplasia cancer?
No. Intestinal metaplasia is not stomach cancer.
But it is regarded as one of the pre-cancerous changes in the lining that can be seen in the development of stomach cancer. This phrase is sometimes misunderstood:
“Pre-cancerous” does not mean “will certainly become cancer”
The great majority of people with intestinal metaplasia never develop stomach cancer.
What is the risk of it becoming cancer?
Studies differ, and the risk also varies with the person’s features. According to the pooled data used by the AGA, the risk of developing stomach cancer in people with intestinal metaplasia is roughly:
| Follow-up period | Risk of developing stomach cancer |
|---|---|
| 3 years | 0.4% |
| 5 years | 1.1% |
| 10 years | 1.6% |
The average annual risk of progression has been calculated at about 0.16%.
Put another way, in an average-risk group, the great majority of 100 patients with intestinal metaplasia will not develop stomach cancer within 10 years. But these are population averages; an individual’s risk can be lower or higher.
How many years before intestinal metaplasia turns into cancer?
There is no fixed period such as “3 years”, “5 years” or “10 years”. Intestinal metaplasia is not a condition that turns directly and inevitably into cancer.
The classic sequence can run roughly as follows:
Chronic gastritis → atrophic gastritis → intestinal metaplasia → dysplasia → stomach cancer
But not every patient goes through all of these steps. The process can take years, even decades, and in many people progression never happens at all.
So telling a patient “intestinal metaplasia turns into cancer in 5 years” is not scientifically correct.
In whom is the risk of cancer higher?
The risk can be increased particularly where there is:
- Widespread intestinal metaplasia
- Metaplasia in both the antrum and the corpus
- Incomplete-type intestinal metaplasia
- Advanced atrophy
- Advanced histological stages such as OLGA/OLGIM III–IV
- A history of stomach cancer in a first-degree relative
- Ongoing H. pylori infection
- Smoking
- Coming from a region at high risk of stomach cancer
Widespread intestinal metaplasia in particular matters more than metaplasia confined to a small, limited area.
What should be done if H. pylori is present?
H. pylori should be looked for and treated if found. Both the AGA and current European guidelines recommend testing for H. pylori in patients with intestinal metaplasia and eradicating it when found.
Confirming by an appropriate method that H. pylori really has been eliminated after treatment also matters.
Does intestinal metaplasia go away?
Some studies have reported histological regression over time; but there is no guarantee that intestinal metaplasia will disappear completely.
The main aim of treating H. pylori is not only to remove the existing metaplasia but to reduce ongoing inflammation and future risk. So it is not right to say “I treated the H. pylori, so the metaplasia has certainly gone.”
Is endoscopic follow-up needed?
The same follow-up programme is not applied to every patient with intestinal metaplasia. There are some differences here between American and European approaches.
According to the 2025 European MAPS III guideline, follow-up with high-quality endoscopy roughly every 3 years is recommended where intestinal metaplasia involves both the antrum and the corpus, where there is advanced histological stage, or where the changes are widespread.
By contrast, routine endoscopic follow-up is not recommended in patients with mild to moderate intestinal metaplasia confined to the antrum who have no additional risk factors such as family history, incomplete metaplasia or ongoing H. pylori.
The AGA, meanwhile, does not recommend routine endoscopic follow-up for all patients with intestinal metaplasia; it states that follow-up may be carried out in high-risk patients by shared decision-making between patient and doctor. If follow-up is chosen, an interval of 3–5 years may be considered.
So “if there is intestinal metaplasia, an endoscopy is needed every year” is not correct.
How should endoscopic follow-up be done?
Where follow-up is needed, an ordinary gastroscopy simply “to see whether anything has changed” may not be enough.
The current European guideline recommends high-quality endoscopic examination and, in suitable patients, the use of image-enhancement techniques. The different regions of the stomach should be examined carefully and appropriate biopsies taken from the necessary areas.
Taking biopsies from separate regions in the antrum/incisura and the corpus helps determine whether the intestinal metaplasia is limited or widespread. That distinction can directly affect the decision about follow-up.
What should be looked at in the pathology report?
Looking only at the sentence “intestinal metaplasia is present” is not enough. The extent of the metaplasia, whether it is complete or incomplete, atrophy, dysplasia and H. pylori status all matter in particular.
“Dysplasia” is a different and more important finding
If the pathology report shows dysplasia, the approach to assessment and follow-up differs from that for intestinal metaplasia.
Remember
- Intestinal metaplasia Is not stomach cancer.
- The average annual risk of progression Is about 0.16%; the pooled 10-year risk is about 1.6%.
- But individual risk Is not the same for everyone.
- If H. pylori is present It should be treated.
- Extent and biopsy results Matter in the decision about follow-up.
- Not every patient Needs a yearly endoscopy.
- In high-risk or widespread metaplasia Endoscopic follow-up every 3 years is an important current approach.
The most important message
Intestinal metaplasia is not cancer, and the great majority of patients with it never develop stomach cancer.
That said, it should not be dismissed as unimportant. H. pylori should be looked for, the extent and type of the metaplasia should be assessed on biopsy, and whether endoscopic follow-up is needed should be decided according to the patient’s individual risk.
This is not enough to make a diagnosis
The decision about follow-up for intestinal metaplasia is not made simply from the presence of that word in a pathology report. The quality of the endoscopy, where the biopsies were taken, the extent of the atrophy and metaplasia, whether there is dysplasia, H. pylori status and family history all have to be weighed together.
Sources
- Prof. Ali Tüzün İnce, MD